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ABSTRACT
Active national pharmacovigilance programmes are needed to monitor adverse drug reaction (ADR)
data in local populations. The objective of this study was to describe the knowledge, experiences, attitudes and perceived barriers to reporting of suspected ADRs by community and hospital pharmacists in
West Bank, Palestine. Between December 2014 and March 2015 we conducted a survey about the
knowledge and attitude of pharmacists (n = 270) using a face-to-face questionnaire. The questionnaire
consisted of questions about the sociodemographic characteristics of the pharmacists, their knowledge of
pharmacovigilance and their attitudes towards ADR reporting. Main outcomes measured: The majority of
the pharmacists (62.6%) worked in the community pharmacies and more females responded to the questionnaire than males (59% vs 41%). only 11.9% could conceptually or actually define
‘pharmacovigilance’ correctly while one quarter of the respondent pharmacist (24.9%) could define ADR
correctly. The hospital clinical pharmacists defined ‘pharmacovigilance’ correctly with higher significance (P<0.001) when compared with community pharmacists. Only 12.2% had ever reported an ADR.
The majority of these reports (85%) done by the hospital pharmacists (p<0.0001). The main reasons that
discourage the pharmacists from reporting ADRs were ‘‘no enough information available from the patient
(76.7%)’’, and ‘‘they did not know how to report (66.7%)’’. The majority of the respondents (92.0%) felt
that reporting ADR was their duty and (82%) participants were interested in participating in the National
Pharmacovigilance Programme in Palestine. The results show that Palestinian pharmacists have poor
knowledge about pharmacovigilance. There is an urgent need for educational programs to train them
about pharmacovigilance and ADR reporting scheme.
Keywords: Pharmacovigilance, Adverse Drug Reaction, Reporting, Palestine.
INTRODUCTION
Adverse drug reactions (ADRs) are encountered commonly in daily practice, many of
which are preventable (1, 2, 3). A study by
Arulumani et al. indicates that 3.4% of the hospital admissions may be attributed to ADRs. In
addition, 3.7% of hospital patients developed
ADRs during their hospital stay (4). It is obvious that ADRs constitutes an economic burden
on the health care system not to mention the obvious morbidity and mortality associated with
ADRs (5, 6). Thus, early detection and prevention of ADR may be necessary.

Traditionally, the role of the pharmacist was
limited to the preparation and dispensing of
drugs prescribed by the physician. Recently, the
role of the pharmacist has expanded to other aspects of patient care (7, 8). These roles include
reporting ADRs, improving patients’ health, and
economic outcomes. Pharmacists can play an
important role in ADR reporting and
pharmacovigilance by increasing the number as
well as the quality of submitted reports (9, 10).
However, in many countries the knowledge of
pharmacists about pharmacovigilance and ADR
reporting is poor and the rate of reporting is low
(11, 12, 13).
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Till this published paper, there is no
pharmacovigilance center in Palestine; however
efforts from the Palestinian Ministry of Health
and Pharmacist association are commence to
establish a Palestinian pharmacovigilance center.
In order to enhance the role of health professionals in spontaneous reporting in the near future, it might be necessary to conduct an analysis
of practice; attitude and knowledge of health
care professional in order to design strategies
that modify and enhance reporting.
Evaluating the knowledge, behaviors and
experiences of pharmacists relating to spontaneous reporting of ADRs is very important and
lacking in Palestine. When pharmacists have
sufficient knowledge of the ADR reporting process, they can improve other healthcare professionals’ knowledge about ADR reporting (14).
To the best of our knowledge no studies have
evaluated pharmacists’ knowledge and attitudes
toward ADRs reporting in the hospital and
community settings in Palestine. Our study was
in the unique position to assess their understanding and knowledge about the Pharmacovigilance
and spontaneous ADRs reporting scheme.
Therefore the objective of this study was to describe the knowledge, experiences, attitudes and
perceived barriers to reporting of suspected
ADRs by community and hospital pharmacists
in West Bank, Palestine.
MATERIALS AND METHODS
Study design, settings and study subjects
This is a cross-sectional study that was conducted in four of the largest cities in West Bank
Palestine; Ramallah, Hebron, Bethlehem and
Nablus. The study commenced in December
2014 and continued for 3 months. Two hundred
and seventy (270) pharmacists were included in
the study with a response rate of 77.1%. Pharmacists from all specialties working in hospitals,
independent and chain pharmacies were enrolled
in the study after obtaining an informed consent.
Those who were not willing to participate or did
not return the questionnaire within the stipulated
time were excluded.

Questionnaire
The final form of the questionnaire consisted of 25 questions was designed using the precedence set by similar studies, (15-18) to obtain
information regarding the demographics of the
respondents, knowledge regarding the ADR reporting system, attitude and practice of ADR
reporting, and the factors that encouraged and
discouraged reporting. Content validity was assessed by distributing the questionnaire to small
randomly selected group of Palestinian pharmacists recruited to complete the validation process. The initial draft of questionnaire was hand
delivered to those pharmacists to help review the
structured questionnaire and perform any
amendments needed.
Data collection and ethical consideration
Well trained team consists of four pharmacist researchers visited each pharmacy and invited community and hospital pharmacists to participate in the study after explaining the aims of
the study. A written consent form was obtained
from each participant who wished to participate
in the study. Participants were told that all information provided was completely confidential
and the results would be presented anonymously.
Statistical Analysis
Student’s t-test was used to compare continuous data. The x2 test was used to compare
categorical data. All p-values presented are twotailed. P-Values<0.05 were considered statistically significant. The analyses were performed
using SPSS version 19.0.
RESULTS
Demographics
A total of 350 registered pharmacy practitioners were approached. Only 270 responded to
the survey with 270 pharmacists having all questions completely answered. The average response rate was 77.1%. The demographics of the
respondents are presented in Table 1. The mean
age of the pharmacists was 32.9 (SD=6.5) years,
with varying degree of education, 77% with
Bachelor degree in Pharmacy, 11% with Master
Degree; 4% with Pharm. D. and only 2% with
Ph.D. More females responded to the question-
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naire than males (59% vs 41%). The majority of
the pharmacists (62.6%) worked in the community pharmacies and their experience in practice
ranged from 1 to 26 years, the median years of
experience were 6.8 years.
Table (1): Demographic information for participated Pharmacists (n=270).
Variables
Age (in years)
20-29
30-39
>40
Mean (SD)
Gender
Female
Male
Experience (in years)
<5
5-10
>10
Degree of education
Diploma
Bachelor degree
Master degree
Pharm D degree
PhD degree
Employment status
Community Pharmacy
Hospital Pharmacy
pharmaceutical industry
sales and marketing
Academic

Frequency (%)
143
99
28
33.1

(53.0)
(36.7)
(10.4)
(5.8)

159
111

(58.9)
(41.1)

61
(22.6)
136 (50.4)
73 (27.0)
8 (2.9)
213 (78.9)
27 (10.0)
16 (6.0)
6 (2.2)
169 (62.6)
79 (29.3)
10 (3.7)
8 (2.9)
4 (1.5)

SD: Standard Deviation, Pham D: Doctor of
Pharmacy. PhD: Doctor of Philosophy.

Pharmacist counseling, knowledge regarding
pharmacovigilance and ADR reporting
Pharmacists were asked to define the terms
‘pharmacovigilance’ and ‘adverse drug reaction’. The open-ended questions were evaluated
according to the WHO’s definition.
Of the responding pharmacists, only 11.9%
could conceptually or actually define
‘pharmacovigilance’ correctly while one quarter
of the respondent pharmacist (24.9%) could define ADR correctly. The hospital clinical pharmacists defined ‘pharmacovigilance’ correctly
with higher significance (P<0.001) when compared with community pharmacists. Significant
difference was also found between the Pharm D
Pharmacists and Bachelor degree pharmacist
(P<0.001) for the definition of ADR. Only 23
(22%) of the participants said that they were familiar with the ADR reporting process. The responses to knowledge items are illustrated in
Table 2; about half of the pharmacists only ever
discuss ADR with the patients, prescribers or
colleagues. Very few (11.2%) of the participants
said they reported ADRs when they occurred
and most of those from hospital pharmacists
(p<0.0001). The main reasons for not reporting
ADRs; (71.5%) said that they were not aware of
the method of reporting, (11.6%) said that ADR
reporting was the duty of physicians and hospital
pharmacists, and 4 (8.3%) said that all ADRs
are familiar and already reported in the medication leaflet.

Table (2): Patient counseling about ADR, n(%) for 270 respondents.
Questions

Never

Rarely

Sometimes

Frequently

Always

How often do you ask your patient if
he/she is allergic to medications?
How often do you ask a female if she
is
pregnant
when
dispensing
teratogenic/ abortive medication?
How often do you counsel your patients about ADRs that they may experience from their medication?
How often do you discuss an ADR
with your pharmacist colleague?
How often do you discuss an ADR
with the prescriber?

0

24 (8.8)

81 (30.0)

65 (24.1)

100 (37.0)

0

11 (4.1)

43 (15.9)

81 (30.0)

135(50.0)

3 (1.1)

24 (8.8)

52 (19.3)

78 (28.9)

113 (41.9)

13(4.8)

24 (8.8)

54 (20.0)

75 (27.8)

104 (38.5)

27 (10.0)

83 (30.7)

68 (25.2)

41 (15.2)

51 (18.9)

ADR: Adverse Drug Reaction
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Experience of ADR reporting
The experience and practice of ADRs reporting by pharmacists is shown in Table 3. It is
obvious that about (245, 90.7%) of the pharmacists had noticed at least one ADR in a patient
per a year, while only (33, 12.2%) had ever re-

ported an ADR. The majority of these reports
(85%) done by the hospital pharmacists
(p<0.0001). Reporters mostly submitted their
documentation to their hospitals, but also some
submitted directly to the drug manufacturer.

Table (3): Pharmacists Practice toward ADRs reporting procedure.
Questions
Number
How often do the patients report you ADRs of medications?
More than once a week
62
Once a month
83
A few times a year
100
Never
25
Have you ever reported any ADR??
Yes
33
No
237
Do you know what is the period within which you should report a
serious ADR experienced by a patient?
Yes
14
No
256
Do you know to whom you should report the ADRs?
The Ministry of health (MOH)
87
The pharmaceutical association
25
Drug Company
127
Prescriber
27
Others
4
How do you prefer to report the ADRs?
A phone call to drug company
70
The representative of the drug company
57
Using adverse drug reaction reporting form
102
Mail via internet
35
Others
6

%
23.0
30.7
37.0
09.3
12.2
87.8

5.2
94.8
32.2
9.3
47.0
10.0
1.50
25.9
21.1
37.8
13.0
2.2

ADRs: Adverse Drug Reactions.
Pharmacists were also asked about their preferred method of reporting ADR, 37.8% of them
believed that using a specific form was their preferred method of reporting, while 25.9%, 21.1%,
and 13.0% preferred to report via phone calls to
the drug company, informing the representative
of the drug company verbally or by using internet, respectively

Pharmacists Attitudes toward
Pharmacovigilance and ADR reporting process
There were 7 questions related to the perceptions of the pharmacists towards ADR reporting and pharmacovigilance. In general, the
respondents had a positive attitude towards ADR
reporting and pharmacovigilance. The majority
of the respondents (92.0%) believed that we
need a pharmacovigilance centre in this country
and (87%) felt that reporting ADR was their duty. n (82%) participants were interested in par-
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ticipating in the National Pharmacovigilance
Programme in Palestine. However, the majority
felt that they weren’t adequately trained in ADR
reporting process. The details regarding the re-

sponses of pharmacists about their attitudes towards ADR reporting and pharmacovigilance
are listed in Table 4.

Table (4): Pharmacists’ attitudes towards the reporting of suspected ADR’s (n=270).
Questions
Do you believe that we need a
pharmacovigilance centre in this country
Do you think reporting ADR is a pharmacist’s
duty?
Do you believe reporting ADRs will improve
patient safety?
Are you interested in participating in the ADRs
reporting system?
Reporting ADRs causes inconvenience in the
working place
Do you feel that you are adequately trained in
ADR reporting?
Does your workplace encourage you to report
an ADR?

Yes

No

Not Sure

248 (91.9)

13 (4.8)

9 (3.3)

221 (81.9)

24 (8.9)

25 (9.3)

256 (94.8)

11 (4.1)

3 (1.1)

221 (81.9)

32 (11.9)

17 (6.3)

24 (8.9)

218 (80.7)

28 (10.4)

32 (11.9)

229 (84.8)

9 (3.3)

221 (81.9)

32 (11.9)

17 (6.3)

ADRs: Adverse Drug Reactions
Factors influencing the pharmacists to report ADRs were evaluated in this study. Most
of pharmacist indicated that they report reactions
of serious nature, unusual reactions, and reactions that have been not reported before. Factors
that may discourage the pharmacists to report

ADRs were also illustrated in table 5. The main
reasons that discourage the pharmacists from
reporting ADRs were ‘‘no enough information
available from the patient (76.7%)’’, ‘‘they did
not know how to report (66.7%)’’ and ‘‘The
ADR is too trivial to report (67.1%).

Table (5): Factors that may discourage pharmacists to report ADRs.
Item
Uncertain association between the drug and the adverse
reaction
The ADR is too trivial to report
Concern that a report will generate extra work
Lack of confidence in discussing the ADRs with the prescriber
No enough information available from the patient
Lack of time to fill in a report
Fear of legal liability / Fear of facing legal problems
Consider it the doctors’ responsibility
Did not know how to report

Agree

Disagree

Not Sure

153 (56.7)

86 (31.9)

31 (11.5)

183 (67.8)
89 (33.0)

68 (25.2)
148 (54.8)

19 (7.0)
33 (12.2)

137 (50.7)

113 (41.9)

20 (7.4)

197 (73.0)
116 (43.0)
121 (44.8)
35 (13.0)
191 (70.7)

59 (21.9)
132 (48.9)
118 (43.7)
213 (78.9)
54 (20.0)

14 (5.2)
22 (8.1)
31 (11.5)
22 (8.1)
25 (9.3)

ADRs: Adverse Drug Reactions.
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DISCUSSION
According to our knowledge, this is the first
study from West Bank, Palestine which evaluates the Knowledge, practice and attitudes of the
pharmacists towards pharmacovigilance. The
present study firstly demonstrates that the majority of the pharmacists in West Bank have insufficient knowledge about pharmacovigilance and
ADRs reporting process. There are several reports from other countries which commonly emphasize the problem of the ADR under-reporting
among pharmacists (19-22).
Despite the lack of knowledge in the majority of pharmacists, the present study revealed
that hospital pharmacists was better knowledgeable compared to community pharmacists in
ADR reporting procedures. This may be attributed to the fact that hospital pharmacists are
in direct contact with other health care professionals such as physicians and nurses who are
more often involved in the identification of potential ADRs, thus they are more exposed to situations where there is a need to manage or to
report such adverse effects.
Previous study showed that hospital pharmacists report 20 times more frequently than
community pharmacists, this was due to the fact
that the hospital pharmacist was better educated
and informed about pharmacovigilance practice
(19).
About half of the pharmacists 47% in this
study believed that if they want to report ADRs
they will send their report to drug Company or
their representatives; this revealed the need for
authorized organization for reporting ADR in
Palestine.
Spontaneous reporting programs are the
most widely reporting programs operate on the
basis that all ADRs should be reported despite
uncertainty about a causal relationship. Even in
the
developed
countries
where
the
pharmacovigilance
programs
are
wellestablished, a high level of under‑reporting is
documented (23-25). The majority of study participants believed of the importance of the presence of pharmacovigilance center in this country
and considered ADRs reporting to be a natural

task for pharmacists, as well as main responsibility of all healthcare providers, however ADRs
reporting is extremely low regardless these positive attitudes, similar to other studies (20, 26).
However Pharmacist can play a major role in
preventing ADRs reporting. In the developing
countries, patients prefer to contact pharmacists
first for any consultation regarding their medications because they easily accessed healthcare
providers. Therefore, pharmacists need to take a
more active role in the assessment and decision
making concerning the safety of patient medications.
In the present study it was noted that also
hospital
pharmacists
have
insufficient
knowledge of pharmacovigilance practices and
reporting process. The main reasons for underreporting of ADRs are no enough information available from the patient, they did not
know how to report and the ADR is too trivial to
report. These findings were similar to results of
a study performed on pharmacists in other countries (27-29). Pharmacists and other healthcare
providers should consider ADRs reporting as an
obligation at their working places and ADRs
reporting systems in hospitals should be a priority basis for the success of the pharmacovigilance
programs and the better clinical management of
the patients.
Previous studies have demonstrated that
knowledge and attitudes play an important role
on ADR reporting (19). Furthermore, attitudes
may be modifiable variables. Granas et al. (20)
have shown that pharmacists’ reporting-related
attitudes can be significantly modified in a positive manner following educational programs that
influence the ADR reporting. Developing a
written hospital policy, better cooperation with
clinicians, training, simplifying the system, allocation of time for ADR reporting, publicity and
Promotion will improve the ADR reporting
among Pharmacists and other healthcare professionals. In this country further studies needed to
evaluate the influence of the education and training programs on the ADR reporting behaviors.
The main limitations of this study that the
study findings could not be generalized to all
community and hospital pharmacists as more
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national studies needed. Also we are aware of
some methodological weaknesses of our study;
as the questionnaire relied on pharmacists’ selfrated assessment of their own practice and attitudes, pharmacists might have been unwilling to
reveal their practice deficiencies.

7)

8)

CONCLUSIONS
The results show that Palestinian pharmacists
have
poor
knowledge
about
pharmacovigilance. There is an urgent need for
educational programs to train them about
pharmacovigilance and ADR reporting scheme.
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